Quantification of prostate cancer Gleason pattern 4 to predict oncological outcome
BJU International · 2025-12 · 136 (6) · 1057-1063
DOI: 10.1111/bju.16884 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJU International, online erschienen am 07.08.2025. Verfasst von Jonathan Olivier und 7 weiteren Autor:innen. Beteiligte Einrichtung: Urology Department, Claude Huriez Hospital, CHU Lille, Lille, France. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Objectives
To determine if quantifying Gleason pattern 4 (GP4) is superior to Grade Group (GG) in predicting any and distant metastatic recurrence after radical prostatectomy (RP) for prostate cancer, and compare various GP4 quantification methods for predicting metastatic recurrence using preoperative targeted biopsy and magnetic resonance imaging (MRI) data. Patients and Methods We conducted a retrospective study of patients who underwent MRI‐guided biopsies and RP from 2009 to 2018. Patients with GG 2–4 without GP5 disease on biopsy and/or RP specimen were included. The predictors compared were biopsy GG, percentage of GP4 in biopsy cores, millimetres of GP4 in biopsy cores, and volume of GP4 based on MRI lesion volume. These methods were also compared to the Cancer of the Prostate Risk Assessment (CAPRA), International Staging Collaboration for Cancer of the Prostate (STAR‐CAP), European Association of Urology (EAU), and National Comprehensive Cancer Network (NCCN) risk classifications. The C‐index for each model was calculated to evaluate discrimination performance.
Results
A total of 446 patients were analysed, with a median follow‐up of 6.9 years for patients without an event; 46 patients developed any metastasis. For any metastatic recurrence based on biopsy findings, the CAPRA score (C‐Index = 0.72) showed the highest discrimination among risk scores, surpassing biopsy GG (C‐Index = 0.70), but was outperformed by percentage GP4 (C‐Index = 0.74), millimetres GP4 (C‐Index = 0.77), and volume of GP4 (C‐Index = 0.80).
Conclusion
For patients with GG 2–4 prostate cancer containing GP4, preoperative GP4 volume estimation using MRI and targeted biopsy outperforms Gleason scoring classification and standard risk scores in predicting any and distant metastatic recurrence. Further research is warranted on the best methods to quantify GP4 before incorporation in treatment decision‐making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Urology Department, Claude Huriez Hospital, CHU Lille, Lille, France.
- University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France.
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Urology Department, Hôpital Privé La Louvière, Lille, France.
- Radiology Department, Claude Huriez Hospital, CHU Lille, Lille, France.
- Department of Pathology, CHU Lille, Université de Lille, Lille, France.
ORCID-Profile: Andrew Vickers
Förderung
- NCI NIH HHS
Zitieren
APA
Olivier, J., Vertosick, E., Delobel, L., Bommelaere, T., Puech, P., Leroy, X., Vickers, A., & Villers, A. (2025). Quantification of prostate cancer Gleason pattern 4 to predict oncological outcome. BJU International, 136(6), 1057-1063. https://doi.org/10.1111/bju.16884
Vancouver
Olivier J, Vertosick E, Delobel L, Bommelaere T, Puech P, Leroy X, et al. Quantification of prostate cancer Gleason pattern 4 to predict oncological outcome. BJU International. 2025;136(6):1057-1063. doi:10.1111/bju.16884
BibTeX
@article{Olivier2025,
author = {Olivier, Jonathan and Vertosick, Emily and Delobel, Luc and Bommelaere, Thomas and Puech, Philippe and Leroy, Xavier and Vickers, Andrew and Villers, Arnauld},
title = {Quantification of prostate cancer Gleason pattern 4 to predict oncological outcome},
journal = {BJU International},
year = {2025},
volume = {136},
number = {6},
pages = {1057--1063},
doi = {10.1111/bju.16884}
}
EUVIMED